Puma Bio stock: buy or sell?

PBYI stock price: $7.88 5.91% At close on December 6th, 2019

Updated on:
December 6th, 2019

0

After sliding a hair-raising -20.30% yesterday, Puma Bio closed today at $7.88 and climbed an astounding 5.91%.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care.

Should I buy Puma Bio stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Puma Bio stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Puma Bio stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we collected 10 ratings published for PBYI stock in the last 30 days.

The general sentiment of these ratings is bearish for PBYI stock, with 4 negative ratings.
Is PBYI a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-9Cowenn/aHold
2019-8-9Barclaysn/aUnderweight
2019-8-9Barclaysn/aUnderweight
2019-8-12JPMorgan Chase & Co.n/aSell
2019-7-5Cowenn/aHold
2019-5-29Goldman Sachs Groupn/aNeutral
2019-5-10JPMorgan Chase & Co.n/aUnderweight
2019-5-10CitigroupBuyNeutral
2019-3-1Cowenn/aHold
2019-3-1CitigroupBuyBuy

Puma Bio stock analysis

Daily outlook

After sliding a hair-raising -20.30% yesterday, Puma Bio closed today at $7.88 and climbed an astounding 5.91%.

After sliding a hair-raising -20.30% yesterday, Puma Bio closed today at $7.88 and climbed an astounding 5.91%. Since price and SMA100d lines crossed down on Tuesday, PBYI fell $-2.85 per share (-26.56%).

PBYI stock chart (daily)

Weekly outlook

Puma Bio collapsed a bloodcurdling -16.97% this week. By mid November PBYI skyrocketed a dazzling 13.10% in just one week.

Since price and 40-weeks moving average lines crossed down early April, PBYI fell $-27.58 per share (-77.78%). Stocks under the 200 days moving average line are usually not recommended for average traders.

PBYI stock chart (weekly)

Puma Bio stock price history

Puma Bio IPO was on April 24th, 2012 at $13.00 per share1. Since then, PBYI stock declined a -39.40%, with a yearly average of -5.60%.

1: Adjusted price after possible price splits or reverse-splits.

Puma Bio stock historical price chart

PBYI stock reached 52-week highs on March at $43.90, and all-time highs 2014-08-26 with a price of 279.37.

Puma Bio stock price target is $29.40

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' PBYI stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 9 price forecasts for PBYI stock:
PBYI stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-9CowenReiteratesn/a$25.00-
2019-8-9BarclaysReiterates$21.00$9.00-57.1%
2019-8-9BarclaysLowers Target$21.00$9.00-57.1%
2019-8-12JPMorgan Chase & Co.Reiteratesn/a$13.00-
2019-7-5CowenReiteratesn/a$28.00-
2019-5-29Goldman Sachs GroupLowers Target$29.00$24.00-17.2%
2019-5-10JPMorgan Chase & Co.Lowers Target$27.00$19.00-29.6%
2019-3-1CowenReiteratesn/a$68.00-
2019-3-1CitigroupRaises Target$67.00$70.004.5%
(in average)$33.00$29.40-11.0%
Moving in a range from $70.00 and $9.00, the price forecast for PBYI stock is $29.40. In average, analysts' outlook on PBYI price forecast is negative, reducing the forecast by a -11.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Puma Bio didn't meet the estimates of the analysts and reported an awful EPS of $-0.80 per share when experts were expecting $-0.92.
PBYI earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-1.97n/a
2017-Q2-n/a-2.1n/a
2017-Q32017-11-09-2.58-2.07n/a
2017-Q42018-03-01-1.98-1.71n/a
2018-Q12018-05-09-0.75-0.65n/a
2018-Q22018-08-09-1.26-1.17n/a
2018-Q32018-11-01-1.07-0.37n/a
2018-Q42019-02-28-0.92-0.8n/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to 2017, last anual revenues report draw a dazzling gain of 806.60% to $250.99 M USD. When comparing 2018 vs 2017, similarly, profit margin (that is, the net income divided by revenues) rocketed a 1,009.31% to -45.25%.

PBYI annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2017$28 M-$-291.96 M-1054.6%-
2018$251 M806.60%$-113.58 M-45.3%-61.10%

Quarterly financial results

Puma Bio posted $71.08 million in revenues for 2018-Q4, a 13.49% up compared to previous quarter. Reported quarter income marked $-30.70 million with a profit margin of -43.18%. Profit margin plunged a -20.51% compared to previous quarter when profit margin was -22.67%. When comparing sales to same quarter last year, Puma Biotechnology sales marked an outstanding increase and boosted a 228.95%. Looking back to recent quarterly results, Puma Biotechnology posted 2 negative quarters in a row.
PBYI quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q3$6 M-$-77.18 M-1269.4%-
2017-Q4$22 M255.39%$-64.08 M-296.5%-16.98%
2018-Q1$67 M207.83%$-24.35 M-36.6%-62.01%
2018-Q2$51 M-23.68%$-44.34 M-87.3%82.11%
2018-Q3$63 M23.37%$-14.20 M-22.7%-67.97%
2018-Q4$71 M13.49%$-30.70 M-43.2%116.15%

Puma Bio ownership

When you are planning to buy shares of a stock, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Puma Bio, 13.44% of all outstanding shares are owned by its staff.

Bearish positions for PBYI stock account 0.00%, no big difference from last month.

For a better context understanding, the following table shows ownership data compared to other related stocks:

PBYIDAREGSKPFE
Market cap$307.0 M$16.1 M$113.3 B$210.3 B
Total shares39.0 M19.7 M2,490.0 M5,530.0 M
Float shares30.1 M14.4 M2,450.0 M5,530.0 M
  - Institutional holdings (%)100.9%8.1%11.0%76.2%
  - Insider holdings (%)13.4%16.9%0.0%0.0%
Shares in short selling0.0%0.0%0.0%0.0%

Puma Bio summary

Friday, December 6th, 2019
Open$7.81
Close$7.88
Day range$7.68 - $8.14
Previous close$7.44
Session gain5.91%
Average true range$0.85
50d mov avg$8.23
100d mov avg$9.38
200d mov avg$17.36
Daily pattern
Weekly pattern lb06a

Puma Bio performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Puma Biotechnology, the comparison is made against Dare Bioscience, GlaxoSmithKline and Pfizer.
Stock3m6m12m
PBYIPuma Biotechnolog...-26.77%-43.02%-65.99%
DAREDare Bioscience2.50%-5.75%-4.65%
GSKGlaxoSmithKline9.32%16.96%28.16%
PFEPfizer5.20%-9.71%-10.20%

Puma Bio competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Puma Bio. We picked 3 companies as Puma Bio competitors as they are in the same industry or have similar market objectives.